The overall aim of this work is to understand how biallelic CEBPA mutations block differentiation and contributed to the development of acute myeloid leukemia (AML). This [...]

c-Myc is a key transcription factor regulating hematopoiesis, and its overexpression is common in leukemia. c-Myc stability is controlled by phosphorylation at serine 62 [...]

Acute myeloid leukemia (AML) is a malignancy with a poor survival rate, primarily due to resistance to chemotherapy.Combination therapy using gilteritinib with venetocla [...]

Acute myeloid leukemia (AML) is a form of blood cancer which mostly affects older people and undesirable outcomes of standard chemotherapy approaches are [...]

Identification of druggable mutations in Acute Myeloid Leukemia (AML), such as FLT3-ITD, has led to the development of targeted therapies capable of out-performing cytoto [...]

In this work, I explored epigenetic dysregulation AML by Chromatin dynamics in acute myeloid leukemia subsets defined by genetic and drug response diversity and the ident [...]

In these experiments, I begin to delineate the role of AML-derived exosomes in the regulation of the marrow microenvironment. Through electron and fluoresc [...]

Acute Myelogenous Leukemia (AML) is an aggressive cancer of the bone marrow that affects both adults and children alike. While many patients achieve remission following i [...]

This thesis describes fibroblast growth factor signaling in the development of resistance to tyrosine kinase inhibitor therapy in solid and hematologic malignancies, and [...]

Acute Myeloid Leukemia (AML) is an aggressive cancer with poor overall survival due to frequent relapse. FMS-like tyrosine kinase (FLT3) is the most commonly mutated gene [...]